

Aurora Cannabis (NASDAQ/TSX: ACB) - Fiscal Q1 2027 Results & Valuation

Fiscal first quarter ended June 30, 2026, reported in Canadian dollars under IFRS. Aurora is a Canadian medical-cannabis company pivoting to a global medical pure-play: it is exiting consumer cannabis and has divested plant propagation (the Bevo stake was sold in February 2026) to focus on medical markets in Canada, Germany, Poland, Australia and New Zealand. Net revenue fell 9% as a Canadian reimbursement cut hit medical sales, while international medical grew 17%.

A factual snapshot built from Aurora's public filings and verified market data. It contains no Blackspear forecast, price target, or recommendation.

NET REVENUE (Q1'27) \$67.6M ▼ 9% vs \$74.1M a year ago	INT'L MEDICAL REVENUE \$43.3M ▲ 17%; now 64% of total net revenue	ADJUSTED EBITDA \$3.4M vs \$10.8M a year ago; net loss \$4.0M	CASH & INVESTMENTS \$149.1M no debt; incl \$49.1M restricted cash
---	--	--	--

NET REVENUE BY CATEGORY - Q1 FY2027 (C\$ THOUSANDS)

CATEGORY	Q1'27	Q1'26	CHANGE
International medical	\$43,337	\$37,094	+17%
Canadian medical	\$20,699	\$27,674	-25%
Consumer	\$2,060	\$7,875	-74%
Wholesale bulk	\$1,458	\$1,433	+2%
Total net revenue	\$67,554	\$74,076	-9%

The mix shift is the story: international medical (mainly Germany) is now 64% of total net revenue and growing (68% of medical revenue), while Canadian medical fell 25% after a federal reimbursement program cut rates by roughly 30% effective April 1, 2026, and consumer cannabis is being wound down. Adjusted gross margin before fair-value adjustments was 58% (64% a year ago), pressured by the Canadian reimbursement change.

RESULTS & CASH HIGHLIGHTS - Q1 FY2027

Adjusted gross margin (before FV)	58%
Adjusted SG&A	\$35.1M
Net loss (continuing ops)	\$(4.0)M
Diluted loss per share	\$(0.07)
Free cash flow	\$(5.8)M
Working capital / inventory	\$320M / \$164M

Profitability fell sharply year-over-year (adjusted EBITDA \$10.8M to \$3.4M) and free cash flow was an outflow of \$5.8M, mainly on the lower Canadian reimbursement rates. The balance sheet is debt-free: \$149.1M of cash and investments (including \$49.1M restricted) and no debt.

HOW TO READ THE NUMBERS

- Figures are in Canadian dollars under IFRS; the shares trade in US dollars on NASDAQ and in Canadian dollars on the TSX.
- "Adjusted" gross margin, EBITDA, SG&A and net income are non-GAAP; IFRS gross margin (after fair-value swings on biological assets and inventory) was 53%.
- Prior-year figures exclude Bevo (plant propagation), divested in February 2026 and shown as a discontinued operation.
- The company is loss-making and burning cash this quarter; the case rests on international medical growth and its cash cushion (see page 2).

STRATEGY, BALANCE SHEET & OUTLOOK - AS OF JUNE 30, 2026

A MEDICAL PURE-PLAY PIVOT, FUNDED BY A DEBT-FREE BALANCE SHEET

CASH & INVESTMENTS

\$149.1M

no debt; \$49.1M of
it is restricted cash

INT'L MEDICAL GROWTH

+17%

Germany-led; EU-GMP
capacity being added

SAFARI ACQUISITION

EU-GMP

closed Apr 2026; 3-yr
cert. received Jul 2026

FY2027 OUTLOOK

Q2 higher

revenue & adj. EBITDA
seen up sequentially

Aurora has reallocated resources to global medical cannabis, exiting the lower-margin Canadian consumer and plant-propagation businesses. The Safari Flower acquisition (closed April 14, 2026) adds a 59,000-square-foot EU-GMP certified facility in Ontario to supply higher-margin international medical markets; the company plans to invest about \$3.5M over three years in it. Management reiterated its unchanged FY2027 outlook and expects fiscal Q2 revenue and adjusted EBITDA to be sequentially higher than Q1. The strategy is unproven and the company remains loss-making.

VALUATION SNAPSHOT - WELL BELOW ITS 52-WEEK HIGH (MID-AUGUST 2026)

Share price (NASDAQ, recent)	US\$3.68	Net revenue (Q1, annualized)	~C\$270M
Market cap (~64.9M sh.)	~US\$239M	EV / revenue (annualized run-rate)	~0.8x
Market cap (C\$ at ~1.37)	~C\$327M	Adjusted EBITDA (Q1)	C\$3.4M
Cash & investments / debt	C\$149.1M / nil	Diluted EPS (Q1, IFRS)	C\$(0.07)
Enterprise value (less unrestricted cash)	~C\$227M	Dividend	none
52-week range (NASDAQ)	US\$2.56-\$6.67	Cash excl. restricted / mkt cap	~31%

Currency: the shares are quoted in US dollars on NASDAQ while the financials are in Canadian dollars; figures here use USD/CAD of about 1.37 as of mid-August 2026, which will change. Aurora trades below ~1x annualized revenue with total cash equal to nearly half its market value (about a third excluding C\$49.1M of restricted cash), but revenue is declining, it is loss-making with negative free cash flow. Multiples are mechanical and move with the price, the cycle and FX, refresh before relying on them.

Full Excel model - linked tabs (segment build, international-medical ramp, margin bridge, cash-runway, valuation, source tie-outs) - available on request. Email info@blackspearllc.com for a copy.


Important disclosures. This material is provided by Blackspear, LLC for general informational and educational purposes only. It is not investment, legal, tax, or accounting advice, is not a research report, and is not an offer, solicitation, or recommendation to buy, sell, or hold any security. Blackspear, LLC is not a registered investment adviser or broker-dealer. Information is drawn from sources believed reliable, principally Aurora's public filings (the fiscal first-quarter 2027 news release dated August 5, 2026, and the interim condensed consolidated financial statements for the three months ended June 30, 2026, prepared under IFRS in Canadian dollars) and third-party market data as of mid-August 2026, but its accuracy, completeness, and timeliness are not guaranteed and it may contain errors or become outdated. Financial figures are in Canadian dollars unless marked US\$; the shares are quoted in US dollars on NASDAQ and Canadian dollars on the TSX, and a USD/CAD rate of approximately 1.37 (mid-August 2026) is used where noted and will fluctuate. "Adjusted gross margin," "adjusted EBITDA," "adjusted SG&A," "adjusted net income," and "free cash flow" are non-GAAP measures defined by Aurora; they are not substitutes for IFRS measures and may not be comparable to similarly named measures at other companies. Aurora is loss-making, reported negative free cash flow in the quarter, and its reported "cash and cash equivalents and short-term investments" of C\$149.1M includes C\$49.1M of restricted cash. Forward statements regarding the fiscal Q2 outlook and international growth are company expectations, are inherently uncertain and subject to revision, and actual results may differ materially. Share price, market capitalization, enterprise value and all multiples are Blackspear calculations using standard methods and are mechanical constructs, not a valuation, forecast, price target, or recommendation. Past performance is not indicative of future results. Recipients should independently verify all figures against the primary filings and consult their own advisers before making any decision. Blackspear, LLC and its principals may hold positions in the securities mentioned and undertake no obligation to update this material.

Aurora Cannabis (NASDAQ/TSX: ACB) - Valuation, the Pivot & Key Risks

A loss-making Canadian cannabis company remaking itself as a global medical pure-play. International medical (Germany-led) is now the largest and fastest-growing segment, while Canadian medical shrinks on reimbursement cuts and consumer winds down. The bull case rests on international growth and a debt-free balance sheet; the bear case on falling revenue, cash burn, and a still-unproven turn.

Figures from Aurora disclosures (Canadian dollars, IFRS) and public market data; the outlook is company guidance; multiples are Blackspear calculations. Nothing here is a Blackspear price target or recommendation.

NET REVENUE BY CATEGORY - Q1 FY2026 VS Q1 FY2027 (C\$M)



EV / REVENUE ~0.8× on ~C\$270M annualized	ADJ. EBITDA (Q1) C\$3.4M was C\$10.8M a year ago	NET CASH (UNRESTR.) ~C\$100M excl. C\$49.1M restricted; no debt	FREE CASH FLOW (Q1) C\$(5.8)M outflow; was +C\$6.8M
---	--	---	---

VALUATION & THE PIVOT

Share price (NASDAQ)	US\$3.68
Market cap (US\$ / C\$ ~1.37)	~US\$239M / ~C\$327M
Cash & investments (incl. restricted)	C\$149.1M / nil debt
Enterprise value (less unrestricted cash)	~C\$227M
Net revenue (Q1, annualized)	~C\$270M
EV / revenue (run-rate)	~0.8×
Int'l medical (Q1'26 → Q1'27)	\$37.1M → \$43.3M
Canadian medical (Q1'26 → Q1'27)	\$27.7M → \$20.7M

A CHEAP-LOOKING TURNAROUND BET

CASH-RICH, BUT LOSS-MAKING AND SHRINKING Below 1x revenue, on an unproven pivot

ACB trades below ~1x annualized revenue with total cash equal to nearly half its market value (about a third excluding restricted cash) and no debt, which looks inexpensive. Bulls point to double-digit international medical growth (Germany), new EU-GMP capacity from the Safari acquisition, and a debt-free balance sheet that funds the transition. Bears note total revenue is still falling, the company is loss-making with negative free cash flow, Canadian medical is eroding on reimbursement cuts, and cannabis names have a long record of dilution and value destruction. The cash cushion buys time; the turn is not yet proven. This frames both sides; it is not a Blackspear view.

TOP RISK FACTORS - SUMMARIZED FROM THE COMPANY'S FILINGS

- ▲ **Profitability and cash burn.** Aurora is loss-making (net loss C\$4.0M) with negative free cash flow (C\$5.8M outflow) and a large accumulated deficit; if losses persist, the cash cushion erodes and further dilutive financing may be needed.
 - ▲ **Concentration on international/Germany.** The growth case leans heavily on EU medical demand, chiefly Germany; regulatory shifts, pricing, competition, or supply constraints there would hit the main growth engine.
 - ▲ **Execution, integration and FX.** The pure-play pivot, consumer wind-down, and Safari integration carry execution risk; results reported in Canadian dollars are also exposed to currency movements versus the euro and US dollar.
- ▲ **Canadian reimbursement and price pressure.** An April 2026 federal reimbursement change cut rates by about 30%, driving Canadian medical revenue down 25%; further policy or pricing changes could keep pressuring the home market.
 - ▲ **Regulation, licensing and quality.** Cannabis is heavily regulated across every market; EU-GMP certification, import/export permits, and product-quality or compliance failures could disrupt supply and sales.
 - ▲ **Dilution, volatility and sector derating.** The share count has grown over time, the stock is volatile (a US\$2.56 to US\$6.67 range in a year), and cannabis equities have broadly derated, offering little valuation support if the turn stalls.

On the numbers. Reported results are from Aurora's fiscal Q1 2027 news release and interim financial statements (three months ended June 30, 2026, IFRS, Canadian dollars). The chart shows net revenue by category (after excise taxes) for the current quarter versus the prior-year quarter; prior-year figures exclude the divested Bevo plant-propagation business. Market cap is the NASDAQ (US dollar) quote; the C\$ conversion and enterprise value use USD/CAD of about 1.37 (mid-August 2026). Enterprise value deducts unrestricted cash only: cash and short-term investments of about C\$100M (excluding C\$49.1M restricted cash) against nil debt; total cash including restricted was C\$149.1M. EV/revenue uses the Q1 net revenue annualized; revenue is currently declining. All are mechanical Blackspear calculations, not estimates, price targets, or recommendations.

Important disclosures. This material is provided by Blackspear, LLC for general informational and educational purposes only. It is not investment, legal, tax, or accounting advice, is not a research report, and is not an offer, solicitation, or recommendation to buy, sell, or hold any security. Blackspear, LLC is not a registered investment adviser or broker-dealer. Reported results are from Aurora's fiscal Q1 2027 news release dated August 5, 2026 and the interim condensed consolidated financial statements for the three months ended June 30, 2026, prepared under IFRS in Canadian dollars. Financial figures are in Canadian dollars unless marked US\$; the shares are quoted in US dollars on NASDAQ and Canadian dollars on the TSX, and a USD/CAD rate of approximately 1.37 (mid-August 2026) is used where noted and will fluctuate. Company statements describing Aurora as a "leading" or "global leader" in medical cannabis are the company's own characterizations and are not independently verified here. Forward statements regarding the fiscal Q2 outlook, international growth, and the Safari acquisition benefits are company expectations and are inherently uncertain, may be revised, and actual results may differ materially. "Adjusted gross margin," "adjusted EBITDA," "adjusted SG&A," "adjusted net income," and "free cash flow" are non-GAAP measures defined by Aurora and may not be comparable to similarly named measures at other companies; the company is loss-making and reported negative free cash flow in the quarter, and its C\$149.1M of cash and investments includes C\$49.1M of restricted cash. Enterprise value, EV/revenue and related figures are Blackspear calculations using standard methods and are mechanical constructs, not a Blackspear valuation, forecast, price target, or recommendation. The "Top Risk Factors" are a plain-language summary of risks described in the company's filings and are not exhaustive. Past performance and historical relationships are not indicative of future results. Recipients should independently verify all figures against the primary sources and consult their own advisers before making any decision. Blackspear, LLC and its principals may hold positions in the securities mentioned and undertake no obligation to update this material.